Every Form 4 that Xylem Inc (XYL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XYL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XYL filings page.
Xylem Inc. (XYL) reported equity awards to EVP & Chief Financial Officer Andrea Michele van der Berg. On September 1, 2026, she received 1,693 shares of common stock as restricted stock units and 6,034 non-qualified stock options with an exercise price of $106.89 per share, all vesting in one-third increments on March 1, 2027, 2028, and 2029. Following these awards, she directly holds 10,691 shares of common stock and 6,034 stock options expiring on September 1, 2036, and no Rule 10b5-1 trading plan is reported.
Xylem Inc. (XYL) reported that executive officer Joseph Patrick Johnston, EVP & President, AW, received equity-based compensation on September 1, 2026. He was granted 645 restricted stock units of common stock and 2,298 non-qualified stock options with an exercise price of $106.89 per share, expiring September 1, 2036. Both the RSUs and options are scheduled to vest in one-third increments on March 1, 2027, 2028, and 2029. Following these awards, he directly holds 2,285 shares of common stock and 2,298 stock options, and no Rule 10b5-1 plan is reported.
Xylem Inc. (XYL) had a Form 4 filed by William K. Grogan, its EVP & Chief Financial Officer, reporting insider ownership information but no reportable transactions in this filing. The report does not show any purchases, sales, option exercises, or other equity movements during the covered period.
Xylem Inc. director D Christian Koch reported an acquisition of 1,247 shares of common stock through an award of restricted stock units valued at $120.27 per share. These units are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders, subject to any timely deferral election under the company’s Deferred Compensation Plan. Following this grant, Koch holds 1,247 shares directly.
Xylem Inc. executive Michael J. McGann, EVP & President, MCS, is identified as a reporting person in a Form 4 that shows no share purchases, sales, grants, exercises, gifts, or other insider transactions for this period. All transaction counts and reported holdings are zero, indicating no change in his ownership position.
Yadav Uday reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Uday Yadav received an equity award in the form of restricted stock units tied to the company’s common stock. The grant covers 1,711 shares at a reference value of $116.88 per share and was issued as compensation, not an open-market purchase.
The award was made under the Xylem 2011 Omnibus Incentive Plan and is scheduled to vest in full on the trading day prior to the company’s 2027 Annual Meeting of Shareholders. Following this grant, Yadav directly holds 10,337 shares of Xylem common stock.
Tretikov Lila reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Lila Tretikov received an equity award of 1,711 shares of common stock in the form of restricted stock units valued at $116.88 per share. These units are scheduled to vest in full on the trading day before the 2027 Annual Meeting of Shareholders, bringing her direct holdings to 10,406 shares including those added through dividend reinvestment.
Peribere Jerome A reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Jerome A. Peribere reported an equity compensation grant. He received 1,711 shares of common stock as a restricted stock unit (RSU) award at a reference price of $116.88 per share under the Xylem 2011 Omnibus Incentive Plan.
The RSUs are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders, with settlement deferred until February 1, 2028. Following the grant, Peribere holds 5,747 shares directly and 27,209 shares indirectly through the Jerome A Peribere 2016 Revocable Trust.
Morelli Mark D reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Mark D. Morelli received an award of 1,711 shares of common stock in the form of restricted stock units valued at $116.88 per share. These units are scheduled to vest in full on the trading day before the 2027 Annual Meeting of Shareholders, with settlement deferred until his Separation from Service. Following this award, he directly holds 8,026 shares, including additional shares from dividend reinvestment.
Harker Victoria D reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Victoria D. Harker received an equity grant of 1,711 shares of Common Stock as a compensation award. The award is structured as restricted stock units under the Xylem 2011 Omnibus Incentive Plan and is scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders. After this grant, she holds 18,586 Xylem shares directly, indicating a routine, plan-based addition rather than an open-market purchase.
Glatch Lisa reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Lisa Glatch received a grant of 1,711 shares of common stock as a restricted stock unit award. The units were valued at $116.88 per share on the grant date and are scheduled to vest in full on the trading day prior to the 2027 Annual Meeting of Shareholders. After this compensation-related award, she directly holds 6,874 Xylem shares.
FRIEL ROBERT F reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Robert F. Friel received an equity award in the form of 2,481 shares of common stock, reported as a grant of restricted stock units valued at $116.88 per share. After this award, he directly holds 38,706 shares, including amounts credited through dividend reinvestment.
The award was granted under the Xylem 2011 Omnibus Incentive Plan and is scheduled to vest in full on the trading day before the 2027 Annual Meeting of Shareholders. Friel has elected to defer settlement of this RSU award until his Separation from Service, meaning he will receive the underlying shares at that later time rather than at vesting.
ELLIS EARL RAY reported acquisition or exercise transactions in this Form 4 filing.
Xylem Inc. director Earl Ray Ellis reported receiving an award of 1,711 shares of common stock as restricted stock units valued at $116.88 per share. These RSUs are scheduled to vest in full on the trading day before the company’s 2027 Annual Meeting of Shareholders.
Ellis has elected to defer settlement of this RSU award until Separation of Service, meaning the actual share delivery is postponed until he leaves service. After this grant and dividend reinvestment adjustments, he now directly holds 6,038 shares of Xylem common stock.
Xylem Inc. senior vice president and chief accounting officer Geri-Michelle McShane reported an open-market sale and an option exercise involving the company’s common stock. She sold 4,269 shares at a weighted average price of $117.46 per share, with individual trades ranging from $117.42 to $118.17.
On the same date, she exercised stock options to acquire 3,147 shares of common stock at an exercise price of $86.76 per share, fully exhausting that option grant. After these transactions, she directly owns 3,605 shares of Xylem common stock.
Xylem Inc. director Jerome A. Peribere executed an open-market purchase of 1,210 shares of common stock at $116.61 per share through the Jerome A Peribere 2016 Revocable TR, an indirect ownership vehicle.
Following this transaction, his indirect holdings through the trust total 27,209 common shares, while a separate line shows 4,036 common shares held directly. The scale of the purchase is modest relative to his overall reported position, indicating a routine addition rather than a transformational change in ownership.
Xylem Inc. SVP and Chief Accounting Officer Geri-Michelle McShane reported a small share disposition tied to taxes, not an open-market trade. On the reported date, 64 shares of Xylem common stock were withheld at a price of $126.19 per share to cover tax liabilities from vesting restricted stock units. After this tax-withholding disposition, she held 4,727 Xylem common shares directly.
Xylem Inc. executive vice president Claudia S. Toussaint reported a tax-related share disposition. On March 5, 2026, 305 shares of common stock were withheld at $126.19 per share to cover taxes on restricted stock units that vested under the Xylem 2011 Omnibus Incentive Plan.
After this withholding, Toussaint directly holds 9,037 common shares and indirectly holds 31,250 common shares through the Claudia S. Toussaint Revocable Trust.
Xylem Inc. executive Hayati Yarkadas reported a small tax-related share disposition. On March 5, 2026, 41 shares of Xylem common stock were withheld to cover tax liabilities tied to the vesting of restricted stock units granted on March 5, 2025 under the Xylem 2011 Omnibus Incentive Plan. After this non-market, tax-withholding disposition, Yarkadas directly owned 33,540 Xylem shares.
Xylem Inc. President and CEO Matthew Francis Pine reported a tax-related share disposition. On the vesting of previously granted restricted stock units, 1,846 shares of Xylem common stock were withheld to cover associated tax liabilities, at a value of $126.19 per share. After this withholding, Pine directly owned 45,105 Xylem shares, and a separate indirect holding line reflects 34,007 shares held through the Matthew F. Pine and Angeles Lopez Guerrero Living Trust.
Xylem Inc. executive Michael J. McGann, EVP & President, MCS, reported a tax-related share disposition. On March 5, 2026, 238 shares of common stock were withheld at $126.19 per share to cover taxes from vesting restricted stock units granted on March 5, 2025. After this withholding, he directly owned 11,987 Xylem common shares.
Xylem Inc. Executive Vice President and Chief Financial Officer William K. Grogan reported a tax-related share disposition. On March 5, 2026, 641 shares of Xylem common stock were withheld at $126.19 per share to cover the tax liability from vesting restricted stock units granted on March 5, 2025.
These shares were withheld under the Xylem 2011 Omnibus Incentive Plan (as amended). After this tax-withholding disposition, Grogan directly owned 39,510 shares of Xylem common stock.
Xylem Inc. executive Meredith Emmerich, EVP & President, Applied Water, reported a tax-related share disposition. On March 5, 2026, 158 shares of common stock were withheld at $126.19 per share to cover taxes due upon vesting of restricted stock units granted on March 5, 2025. After this withholding, Emmerich directly held 5,447 common shares.
Xylem Inc. executive Stacy Cozad reported a small tax-related share disposition. On March 5, 2026, 70 shares of common stock were withheld at $126.19 per share to cover taxes due on the vesting of restricted stock units granted on September 1, 2025. After this withholding, Cozad directly owns 2,233 shares of Xylem common stock.
Xylem Inc. executive Albert Cho reported a tax-related share disposition. The company withheld 177 shares of common stock to cover taxes due on the vesting of restricted stock units, leaving him with 16,411 shares of Xylem common stock held directly.
Xylem Inc. executive Rodney Aulick reported a tax-related share disposition. On March 5, 2026, he disposed of 234 shares of Xylem common stock at $126.19 per share through a tax-withholding transaction tied to vested restricted stock units. After this withholding, he directly owns 73,683 Xylem common shares.
Xylem Inc. executive vice president of strategy Albert Cho reported a mix of equity awards and related tax withholdings. On March 2, 2026 he received non-qualified stock options for 3,713 shares at $128.98 per share and a restricted stock unit award of 1,042 common shares.
Footnotes show several performance-based stock units granted in prior years vested based on Total Shareholder Return, Adjusted EBITDA, Revenue and ESG performance, increasing his common stock holdings. Shares totaling 1,610, 295 and 371 were withheld at $128.98 per share to cover tax liabilities tied to these vestings and restricted stock units. After these transactions, Cho directly owned 16,588 shares of Xylem common stock.
Xylem Inc. Pres. & CEO Matthew Francis Pine reported multiple equity compensation changes. On March 2, 2026, he received a grant of 57,386 non-qualified stock options with an exercise price of $128.98, scheduled to vest in one-third increments on March 1, 2027, 2028 and 2029.
He also acquired 16,105 shares of common stock as awards, and on March 1, 2026 vested performance-based stock units delivered 5,243, 4,328, 2,943 and 2,152 shares tied respectively to Total Shareholder Return, Adjusted EBITDA, Revenue and ESG performance, plus additional shares from dividend reinvestment.
To cover tax liabilities from these vestings, the company withheld 4,927, 847 and 2,316 shares of common stock at $128.98 per share. After these transactions, Pine holds both directly owned shares and an indirect position through the Matthew F. Pine and Angeles Lopez Guerrero Living Trust.
Xylem Inc. executive Meredith Emmerich received new equity awards. On March 2, 2026, Emmerich was granted 5,739 non-qualified stock options with an exercise price of $128.98 per share and 1,610 shares of common stock as a restricted stock unit award.
Both the options and restricted stock units were granted under the Xylem 2011 Omnibus Incentive Plan and are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029. The filing also notes additional common shares from dividend reinvestment.
Xylem Inc. executive Stacy Cozad, EVP & Chief Legal Officer, reported equity awards under the company’s incentive plan. She received 5,570 non-qualified stock options at an exercise price of $128.98 per share and 1,563 shares of common stock as a grant.
Both the options and the restricted stock units are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029. Following these transactions, she directly holds 5,570 options and 2,303 shares of common stock.
Xylem Inc. executive Michael J. McGann reported a mix of equity grants, vesting, and tax-related share withholdings. He received 5,739 non-qualified stock options at an exercise price of $128.98 per share, scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029.
McGann also acquired common stock upon vesting of performance-based stock units granted under the Xylem 2011 Omnibus Incentive Plan, tied to Total Shareholder Return (1,966 shares), Adjusted EBITDA (1,622 shares), Revenue (1,103 shares), and ESG performance (489 shares), plus a 1,610-share restricted stock unit award that vests in thirds on the same 2027–2029 dates. To cover tax liabilities from these vestings, the company withheld 2,073, 213, and 510 shares of common stock at $128.98 per share.
Xylem Inc. EVP & Chief Financial Officer William K. Grogan reported equity compensation grants and associated tax withholdings. On March 2, 2026, he was awarded a non-qualified stock option for 18,228 shares at an exercise price of $128.98 per share, scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029. He also received 5,116 restricted stock units under the same plan, vesting in one-third increments on those same dates. On March 1, 2026, performance-based stock units granted on March 1, 2023 vested upon achievement of Total Shareholder Return, Adjusted EBITDA and Revenue goals, resulting in acquisitions of 5,551, 4,583 and 3,117 shares of common stock, respectively, including additional shares from dividend reinvestment. To cover tax liabilities from these vestings and a prior restricted stock unit grant, 5,888 and 578 shares of common stock were withheld at $128.98 per share. After these transactions, Grogan directly owned 40,151 shares of Xylem common stock and 18,228 options.
Xylem Inc. executive Rodney Aulick reported equity compensation awards and related tax withholding. On March 2, 2026, he received 5,739 non-qualified stock options with an exercise price of $128.98 and 1,610 restricted stock units under the Xylem 2011 Omnibus Incentive Plan.
The new options and RSUs are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029. The filing also shows a disposition of 238 shares of common stock at $128.98 solely to cover tax liabilities from prior RSU vesting, leaving Aulick with 73,917 common shares held directly.
Xylem Inc. EVP and CPSO Claudia S. Toussaint reported equity compensation grants and related tax withholdings. On March 2, 2026, she received 7,089 non-qualified stock options with an exercise price of $128.98 per share, scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029.
She also acquired multiple blocks of common stock upon vesting of performance-based and ESG-related stock units granted in 2021 and 2023 under the Xylem 2011 Omnibus Incentive Plan, and received an additional restricted stock unit award set to vest in three annual tranches beginning March 1, 2027. To cover tax liabilities from these vestings, she disposed of several small blocks of common stock through share withholding at $128.98 per share. Following these transactions, she directly owns 9,342 shares of common stock, and an additional 31,250 shares are held indirectly by the Claudia S. Toussaint Revocable Trust.
Xylem Inc. executive Hayati Yarkadas reported equity awards and related tax withholdings. On March 1 and 2, 2026, he acquired several blocks of Xylem common stock through the vesting of performance-based and other stock units under the Xylem 2011 Omnibus Incentive Plan tied to metrics such as Total Shareholder Return, Adjusted EBITDA, Revenue, and ESG performance.
He also received an award of 8,102 non-qualified stock options at an exercise price of $128.98 per share and an additional award of 2,274 restricted stock units scheduled to vest in three equal installments in 2027, 2028, and 2029. To cover tax liabilities from these vestings, a total of 776 shares of common stock were disposed of through tax-withholding transactions at $128.98 per share. After these transactions, he directly held 33,698 shares of common stock and 8,102 stock options.
Xylem Inc. senior vice president and chief accounting officer Geri-Michelle McShane reported several equity compensation transactions. She received a grant of 2,194 non-qualified stock options with a price of $128.98 per share, scheduled to vest in three annual installments beginning March 1, 2027.
On March 1, 2026, she acquired 721, 595, 405 and 489 shares of common stock upon vesting of performance-based and ESG-related stock units granted under the Xylem 2011 Omnibus Incentive Plan, reflecting achievement of performance goals tied to total shareholder return, adjusted EBITDA, revenue and ESG performance. She also received an award of restricted stock units scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029.
Related to these vestings, 654, 188 and 150 shares of common stock were withheld at $128.98 per share to cover tax liabilities, reducing her directly held common stock to 4,791 shares after the transactions.
Xylem Inc. insider files Form 4 for tax-related share withholding
An executive officer of Xylem Inc. (EVP & President, WSS) reported a routine stock transaction involving company common stock on 01/02/2026. The filing shows that 457 shares of Xylem common stock were withheld at a price of $136.18 per share to cover taxes due when previously granted restricted stock units vested. After this tax withholding, the reporting person directly beneficially owns 72,545 shares of Xylem common stock, which includes additional shares from dividend reinvestment.
Xylem Inc. executive vice president and president of WSS, Rodney Aulick, reported a tax-related share withholding on 12/15/2025. A total of 1,840 shares of Xylem common stock were withheld at $138.25 per share to satisfy the tax liability triggered by the vesting of restricted stock units granted on December 9, 2022 under the Amended and Restated Evoqua Water Technologies Corp. 2017 Equity Incentive Plan, which were converted to Xylem restricted stock units in connection with the merger on May 24, 2023. After this transaction, Aulick directly beneficially owns 72,826 shares of Xylem common stock.
Xylem Inc. (XYL) director Victoria D. Harker reported an open‑market sale of 1,700 shares of common stock at a weighted average price of $148.14 on November 4, 2025. According to the Form 4, the shares were executed within a price range of $148.135 to $148.135.
Following the transaction, Harker beneficially owns 16,875 shares directly. The filing lists no derivative securities transactions.
Xylem Inc. (XYL) reported an insider transaction by EVP, CPSO Claudia S. Toussaint. On 10/30/2025, a revocable trust for which she is trustee sold 10,421 shares of common stock at a weighted average price of $152.64, with executions ranging from $152.51 to $152.98. Following the sale, the filing shows 31,250 shares indirectly owned by the Claudia S. Toussaint Revocable Trust and 3,939 shares directly owned.
Xylem Inc. (XYL) insider filing: EVP & Pres, AW Meredith Emmerich reported a tax withholding transaction tied to RSU vesting. On 10/21/2025, 841 shares of common stock were withheld to cover taxes at a reported price of $147.19 (Transaction Code F).
Following this withholding, the reporting person directly beneficially owns 3,992 shares. The RSUs vested from an award granted on October 21, 2024 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016).